Grifols, S.A. (GRFS)
Market Cap | 5.33B |
Revenue (ttm) | 7.32B |
Net Income (ttm) | 65.91M |
Shares Out | 817.76M |
EPS (ttm) | 0.10 |
PE Ratio | 62.40 |
Forward PE | 14.88 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 838,786 |
Open | 6.33 |
Previous Close | 6.28 |
Day's Range | 6.24 - 6.55 |
52-Week Range | 5.30 - 12.15 |
Beta | 0.67 |
Analysts | Sell |
Price Target | 10.50 (+61.04%) |
Earnings Date | Jul 28, 2022 |
About GRFS
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and... [Read more]
Financial Performance
In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRFS stock is "Sell." The 12-month stock price forecast is $10.5, which is an increase of 61.04% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/p/press18-2507330.jpg)
Probe Into Claims Against Grifols SA Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Contact
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/t/z/biotech12-2507277.jpg)
Unit of Grifols shareholder Scranton reaches debt refinancing deal
Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its un...
![](https://cdn.snapi.dev/images/v1/k/z/press2-2504263.jpg)
Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest, a Grifols...
![](https://cdn.snapi.dev/images/v1/m/n/press3-2502233.jpg)
The Schall Law Firm Begins Probe Into Claims Against Grifols SA And Urges Affected Investors To Initiate Contact
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/h/s/press3-2498955.jpg)
The Schall Law Firm Initiates Investigation Into Allegations Against Grifols SA And Encourages Impacted Investors To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/s/e/press18-2491884.jpg)
The Schall Law Firm Begins Probe Into Claims Against Grifols SA And Urges Affected Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/k/8/press20-2491453.jpg)
The Schall Law Firm Initiates Investigation Into Allegations Against Grifols SA And Encourages Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/a/4/press11-2487014.jpg)
Claims Against Grifols SA The Schall Law Firm Begins Probe And Urges Affected Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/c/t/press17-2485520.jpg)
Allegations Against Grifols SA The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/z/p/press16-2484058.jpg)
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has ...
![](https://cdn.snapi.dev/images/v1/w/q/press9-2483408.jpg)
Claims Against Grifols Sa Schall Law Firm Begins Probe And Urges Affected Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/h/o/press11-2481339.jpg)
Grifols' Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest, a Grifols...
![](https://cdn.snapi.dev/images/v1/d/n/press20-2474576.jpg)
Allegations Against Grifols, S.A.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
![](https://cdn.snapi.dev/images/v1/c/1/press12-2470199.jpg)
Charges Against Grifols, S.A.: Schall Law Firm Launches Examination And Calls On Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/t/s/press8-2469818.jpg)
Accusations Against Grifols, S.A.: Schall Law Firm Initiates Inquiry And Invites Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/0/z/press17-2469348.jpg)
Claims Against Grifols, S.A.: Schall Law Firm Begins Probe And Calls On Affected Investors To Connect
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/q/b/press8-2464533.jpg)
Grifols, S.A. Allegations: Schall Law Firm Commences Probe and Invites Affected Investors to Connect
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/3/m/press12-2462321.jpg)
The Schall Law Firm is commencing a probe into allegations against Grifols, S.A. and invites investors who have suffered losses to get in touch
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/v/j/press5-2460394.jpg)
GRFS IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/u/t/press20-2458038.jpg)
INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/u/q/press20-2457567.jpg)
INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/1/8/press19-2457191.jpg)
INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/g/k/press4-2454646.jpg)
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
![](https://cdn.snapi.dev/images/v1/1/q/press20-2439420.jpg)
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade
![](https://cdn.snapi.dev/images/v1/b/z/press5-2438823.jpg)
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...